Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(19):1410-1412; doi:10.1093/jnci/96.19.1410
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zielinski, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zielinski, S. L.
Related Collections
Right arrowRelated News Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

Despite Positive Studies, Popularity of Chemoprevention Drugs Increasing Slowly

Sarah L. Zielinski

The first 10% of the full text of this article appears below.

Aspirin therapy for people at high risk of heart disease may be the ideal model for preventing disease with pharmaceuticals: It is effective, inexpensive, and has few side effects. However, cancer chemoprevention is a newer concept and far more complicated. The drugs tested so far tend to be more expensive and have more serious side effects than aspirin, and their acceptance by doctors and patients has been slow.

Only a few chemoprevention drugs have so far completed phase III clinical trials. In 1998, the National Surgical Adjuvant Breast and Bowel Project (NSABP) completed its P-1 study of tamoxifen for the prevention of breast cancer in women at high risk. The drug was shown to reduce breast cancer incidence by about 50% compared with placebo and was approved by the U.S. Food and Drug Administration for . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related News Article in JNCI

Money Matters: How Cost-Effectiveness Studies Are Done
Sarah L. Zielinski
J Natl Cancer Inst 2004 96: 1411. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JCOHome page
G. Rondanina, M. Puntoni, G. Severi, C. Varricchio, A. Zunino, I. Feroce, B. Bonanni, and A. Decensi
Psychological and Clinical Factors Implicated in Decision Making About a Trial of Low-Dose Tamoxifen in Hormone Replacement Therapy Users
J. Clin. Oncol., March 20, 2008; 26(9): 1537 - 1543.
[Abstract] [Full Text] [PDF]